The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes - PubMed (original) (raw)

Review

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Daniel J Drucker et al. Lancet. 2006.

Abstract

Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying, and reduces appetite and food intake. Therapeutic approaches for enhancing incretin action include degradation-resistant GLP-1 receptor agonists (incretin mimetics), and inhibitors of dipeptidyl peptidase-4 (DPP-4) activity (incretin enhancers). Clinical trials with the incretin mimetic exenatide (two injections per day or long-acting release form once weekly) and liraglutide (one injection per day) show reductions in fasting and postprandial glucose concentrations, and haemoglobin A1c (HbA1c) (1-2%), associated with weight loss (2-5 kg). The most common adverse event associated with GLP-1 receptor agonists is mild nausea, which lessens over time. Orally administered DPP-4 inhibitors, such as sitagliptin and vildagliptin, reduce HbA1c by 0.5-1.0%, with few adverse events and no weight gain. These new classes of antidiabetic agents, and incretin mimetics and enhancers, also expand beta-cell mass in preclinical studies. However, long-term clinical studies are needed to determine the benefits of targeting the incretin axis for the treatment of type 2 diabetes.

PubMed Disclaimer

Comment in

Gliptins.
Mikhail N. Mikhail N. Lancet. 2007 Jan 27;369(9558):269. doi: 10.1016/S0140-6736(07)60136-6. Lancet. 2007. PMID: 17258655 No abstract available.
Gliptins.
Focosi D, Kast RE, Petrini M. Focosi D, et al. Lancet. 2007 Jan 27;369(9558):269-70. doi: 10.1016/S0140-6736(07)60137-8. Lancet. 2007. PMID: 17258656 No abstract available.
Gliptins.
Grouzmann E, Buclin T, Biollaz J. Grouzmann E, et al. Lancet. 2007 Jan 27;369(9558):269. doi: 10.1016/S0140-6736(07)60135-4. Lancet. 2007. PMID: 17258657 No abstract available.

Cited by

Bitter taste receptors as sensors of gut luminal contents.
Sternini C, Rozengurt E. Sternini C, et al. Nat Rev Gastroenterol Hepatol. 2024 Oct 28. doi: 10.1038/s41575-024-01005-z. Online ahead of print. Nat Rev Gastroenterol Hepatol. 2024. PMID: 39468215 Review.
Establishing a Relationship between In Vitro Potency in Cell-Based Assays and Clinical Efficacious Concentrations for Approved GLP-1 Receptor Agonists.
Boianelli A, Nordell P, Earl J, Naylor J, Hornigold D, Jansson Löfmark R, Sundqvist M. Boianelli A, et al. Pharmaceutics. 2024 Oct 8;16(10):1310. doi: 10.3390/pharmaceutics16101310. Pharmaceutics. 2024. PMID: 39458639 Free PMC article.
Future Perspective: Harnessing the Power of Artificial Intelligence in the Generation of New Peptide Drugs.
Nissan N, Allen MC, Sabatino D, Biggar KK. Nissan N, et al. Biomolecules. 2024 Oct 15;14(10):1303. doi: 10.3390/biom14101303. Biomolecules. 2024. PMID: 39456236 Free PMC article. Review.
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review.
Hamed K, Alosaimi MN, Ali BA, Alghamdi A, Alkhashi T, Alkhaldi SS, Altowarqi NA, Alzahrani H, Alshehri AM, Alkhaldi RK, Alqahtani KW, Alharbi NH, Alhulayfi HF, Sharifi SY, Dighriri IM. Hamed K, et al. Cureus. 2024 Sep 1;16(9):e68390. doi: 10.7759/cureus.68390. eCollection 2024 Sep. Cureus. 2024. PMID: 39355484 Free PMC article. Review.
Mechanisms of ferroptosis and glucagon-like peptide-1 receptor agonist in post-percutaneous coronary intervention restenosis.
Wang M, Wang L, Sun H, Yuan H, Li Y. Wang M, et al. Mol Cell Biochem. 2024 Sep 16. doi: 10.1007/s11010-024-05118-6. Online ahead of print. Mol Cell Biochem. 2024. PMID: 39283562 Review.

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes - PubMed (original) (raw)